Search

Your search keyword '"Plavix (Medication)"' showing total 1,232 results
Start Over Descriptor "Plavix (Medication)"
1,232 results on '"Plavix (Medication)"'

3. GUATEMALAN INSTITUTE OF SOCIAL SECURITY -IGSS- invites tenders for Acquisition of the Medication Clopidogrel, 75 Mg Tablet, Trademark Plavix, Igss Code 185, Required by Different Medical Units of the Institute

Subjects
Company acquisition/merger, News, opinion and commentary, Plavix (Medication)
Abstract

GUATEMALAN INSTITUTE OF SOCIAL SECURITY -IGSS-, Guatemala has invited tenders for Acquisition of the Medication Clopidogrel, 75 Mg Tablet, Trademark Plavix, Igss Code 185, Required by Different Medical Units of [...]

Published
2024

4. Hawaii court orders drug companies to pay $916 million in Plavix blood thinner lawsuit

Subjects
Bristol-Myers Squibb Co. -- Planning, The Associated Press -- Planning, Sanofi S.A. -- Planning, News agencies -- Planning, Pharmaceutical industry -- Planning, Company business planning, General interest, News, opinion and commentary, Plavix (Medication)
Abstract

Byline: The Associated Press HONOLULU (AP) A Hawaii court has ordered the manufacturers and distributors of the blood thinner Plavix to pay the state a combined $916 million after finding [...]

Published
2024

5. United States : More Than $900 Million Against Major Pharmaceutical Manufacturers of Plavix

Subjects
Bristol-Myers Squibb Co., Sanofi S.A., Health care reform, Health care industry, Pharmaceutical industry, Health care industry, Business, international, Plavix (Medication)
Abstract

Hawai?i Attorney General Anne Lopez announced today the entry of an order awarding the state $916,012,000 in total against pharmaceutical companies Bristol-Myers Squibb Company and three U.S.-based subsidiaries of French [...]

Published
2024

7. CytoSorbents to present second analysis from STAR Registry at EACTS meeting

Subjects
Ticagrelor -- Analysis, Business, News, opinion and commentary, Brilinta (Medication), Pradaxa (Medication), Effient (Medication), Savaysa (Medication), Plavix (Medication), Xarelto (Medication)
Abstract

CytoSorbents announced the upcoming original presentations at the 37th European Association of Cardio-Thoracic Surgery Annual Meeting in Vienna, Austria, from October 4-7, 2023, including the second analysis from the international [...]

Published
2023

8. CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

Subjects
CytoSorbents Corp., Banking, finance and accounting industries, Business, Brilinta (Medication), Pradaxa (Medication), Effient (Medication), Savaysa (Medication), Plavix (Medication), Xarelto (Medication)
Abstract

PRINCETON, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via [...]

Published
2023

9. BristolMyers Squibb Co Investor Event - Final

Subjects
Bristol-Myers Squibb Co., Pharmaceutical industry, Business, Plavix (Medication)
Abstract

Presentation TIMOTHY POWER, VP & HEAD OF IR, BRISTOL-MYERS SQUIBB COMPANY: This is Tim Power from Bristol-Myers Squibb. You're very welcome to our presentation at ESC 2022. As you know, [...]

Published
2022

10. EC grants additional indication to Sanofi's Plavix in combo with aspirin in adult patients with moderate to high-risk transient ischemic attack

Subjects
Sanofi S.A., Aspirin, Stroke (Disease), Cerebral ischemia, Clopidogrel, Drug approval, Pharmaceutical industry, Pharmaceuticals and cosmetics industries, European Union. European Commission, Plavix (Medication)
Abstract

Sanofi announced that the European Commission (EC) has approved an additional indication for Plavix (clopidogrel) to include its use in combination with aspirin in adult patients with moderate to high-risk [...]

Published
2021

11. EMA's human medicines committee recommends approval of Sanofi's Plavix with aspirin in adults for certain types of strokes

Subjects
Sanofi S.A., Clinical trials, Clopidogrel, Aspirin, Pharmaceutical industry, Stroke, Adults, Pharmaceuticals and cosmetics industries, Plavix (Medication)
Abstract

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an additional indication for Plavix (clopidogrel) in adult patients with high-risk transient [...]

Published
2020

12. Research from Mashhad University of Medical Sciences Yields New Data on Coumarins and Indandiones (Warfarin interactions: a letter to editor)

Subjects
Physical fitness, Coumarins, Warfarin, Anticoagulants, Ticlopidine, Obesity, Heart transplantation, Drugs, Toxicity, Health, Plavix (Medication)
Abstract

2020 MAY 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on coumarins and indandiones have been published. According to [...]

Published
2020

13. Medicinal notes must ‘be clearer’ after review; Hospital Authority calls for accuracy from staff following wrong treatment for patients

Author

Magramo, Kathleen

Subjects
Medication errors, Medical care -- Quality management, News, opinion and commentary, Plavix (Medication)
Abstract

Hong Kong’s Hospital Authority has reminded staff to clearly note down prescription instructions and store details accurately in record-keeping systems after two recent miscommunications led to wrong medication being given [...]

Published
2021

14. Q3 2020 Sanofi SA Earnings Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry, Business, Dupixent (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Welcome to the Sanofi Investor Call on the Q3 2020 earnings. I would now like to turn the call over [...]

Published
2020

15. Q4 2019 Cytosorbents Corp Earnings Call - Final

Subjects
Chief operating officers, Finance, Company earnings/profit, Business, Plavix (Medication)
Abstract

Presentation OPERATOR: Good afternoon, and welcome to the CytoSorbents 2019 Financial and Operating Results Conference call. (Operator Instructions) Please be advised that the call will be recorded at the company's [...]

Published
2020

16. New Findings from Central South University Update Understanding of Platelet Aggregation Inhibitors (Pharmacokinetics and Bioequivalence of Low-dose Clopidogrel In Healthy Chinese Volunteers Under Fasted and Fed Conditions)

Subjects
Clopidogrel -- Dosage and administration -- Research, Physical fitness, Fibrinolytic agents -- Dosage and administration -- Research, Obesity, Generic drugs, Editors, Health, Plavix (Medication)
Abstract

2019 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Drugs and Therapies - Platelet Aggregation Inhibitors are presented [...]

Published
2019

17. Bristol-Myers, Sanofi must pay $834 million over blood-thinner

Subjects
Bristol-Myers Squibb Co. -- Joint ventures, Sanofi S.A. -- Joint ventures, Consumer protection, Pharmaceutical industry -- Joint ventures, Company joint venture, General interest, News, opinion and commentary, Plavix (Medication)
Abstract

HAWAII Bristol-Myers Squibb and Sanofi were ordered to pay the state of Hawaii more than $834 million for illegally marketing their blockbuster blood-thinning drug Plavix in a manner that put [...]

Published
2021

18. Event Brief of Q3 2019 Sanofi SA Earnings Call - Final

Subjects
Citigroup Inc., Sanofi S.A., Societe Generale S.A., Banking industry, Financial services, Pharmaceutical industry, Financial services industry, Banking industry, Business, Dupixent (Medication), Praluent (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . David Loew - Sanofi,EVP of Pasteur . Dieter Weinand - Sanofi,EVP of Primary Care . George Grofik - Sanofi,Head of IR . Jean-Baptiste Chasseloup de Chatillon - [...]

Published
2019

19. Q3 2019 Sanofi SA Earnings Call - Final

Subjects
Sanofi S.A., Pharmaceutical industry -- International economic relations, Business, Dupixent (Medication), Praluent (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by, and welcome to the Sanofi Third Quarter 2019 Earnings Conference Call. I would like to turn the call over to [...]

Published
2019

20. Event Brief of Q4 2018 Sanofi SA Earnings Call - Final

Subjects
United States. Food and Drug Administration, Societe Generale S.A., Citigroup Inc., Sanofi S.A., Banking industry, Financial services, Pharmaceutical industry, Banking industry, Financial services industry, Business, Cablivi (Medication), Dupixent (Medication), Eloctate (Medication), Plavix (Medication)
Abstract

CORPORATE PARTICIPANTS . Dieter Weinand - Sanofi,EVP . George Grofik - Sanofi,Head of IR . Jean-Baptiste Chasseloup de Chatillon - Sanofi,Executive VP & CFO . John C. Reed - Sanofi,Executive [...]

Published
2019

21. Q4 2018 Sanofi SA Earnings Call - Final

Subjects
United States. Food and Drug Administration, Sanofi S.A., Pharmaceutical industry, Business, Cablivi (Medication), Dupixent (Medication), Eloctate (Medication), Plavix (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, welcome to the Sanofi Q4 and Full Year 2018 Earnings Results Conference Call and Live Webcast. I am Emma, the Chorus Call operator. (Operator Instructions) [...]

Published
2019

22. USING UDAP IN AN ACTION AGAINST THE MANUFACTURERS OF THE ANTIPLATELET MEDICATION PLAVIX

Subjects
Bristol-Myers Squibb Co., Sanofi S.A., Mephenytoin, Exemplary damages, Judgments, Pharmaceutical industry, News, opinion and commentary, Plavix (Medication)
Abstract

WASHINGTON -- The following information was released by the National Association Of Attorneys General: In 2014, the State of Hawai'i sued the manufacturers of the antiplatelet medication Plavix in state [...]

Published
2021

23. Don't look back! what's that image fading from view? Pharma just sped through an unprecedented period of patent expiries, during which some $30 billion in brand revenue went over the cliff. But stay focused on the road. Another patent peak, equally scary, lies ahead

Author

Iskowitz, Marc

Subjects
Merck & Company Inc. -- Intellectual property, Amgen Inc. -- Intellectual property, Bristol-Myers Squibb Co. -- Intellectual property, Pfizer Inc. -- Intellectual property, TEVA -- Intellectual property, Boehringer Ingelheim GmbH -- Intellectual property, AstraZeneca PLC -- Intellectual property, Eli Lilly and Co. -- Intellectual property, Abbott Laboratories (Abbott Park, Illinois) -- Intellectual property, Roche A/S -- Intellectual property, Novartis AG -- Intellectual property, GlaxoSmithKline PLC -- Intellectual property, Forest Laboratories Inc. -- Intellectual property, Cholesterol, Patents, Pharmaceutical industry -- Intellectual property, Patent/copyright issue, Business, Health care industry, Lipitor (Medication), Cymbalta (Medication), Abilify (Medication), Remicade (Medication), Nexium (Medication), Enbrel (Medication), Humira (Medication), Neulasta (Medication), Advair Diskus (Medication), Plavix (Medication), Crestor (Medication), Copaxone (Medication)
Abstract

The sluggish economy, combined with what Michael Klein-rock, director, research development for the IMS Institute, calls 'an unprecedented period of patent expiries,' led to a drop in overall drug spend [...]

Published
2013

24. Top 250 multisource drugs by prescriptions filled

Subjects
Generic drugs, Business, Pharmaceuticals and cosmetics industries, Retail industry, Ventolin (Medication), ProAir HFA (Medication), Singulair (Medication), Proventil (Medication), Cheratussin AC (Medication), Sprintec (Contraceptive), Klor-Con M20 (Medication), Tri-Sprintec (Medication), Plavix (Medication), Tricor (Medication)
Abstract

TOP 250 MULTISOURCE DRUGS BY PRESCRIPTIONS FILLED RANK DRUG SUPPLIER NDC11 NO. PRESCRIPTIONS FILLED * 1 Proair HFA Teva 59310057920 19,797,906 2 Ventolin HFA GlaxoSmithKline 00173068220 16,025,463 3 Singulair Merck [...]

Published
2013

25. FEDERAL COURTS SHOULDN'T 'ABSTAIN' FROM HEARING FEDERAL CIVIL RIGHTS CLAIMS

Subjects
Sanofi S.A., Civil rights -- France, Exemplary damages, Pharmaceutical industry, News, opinion and commentary, Plavix (Medication)
Abstract

WASHINGTON -- The following information was released by the Cato Institute: By Ilya Shapiro and Mallory Reader Hawaii sued Bristol'É Myers Squibb (BMS) and Sanofi for failing to make the [...]

Published
2021

26. United States : $834 Million Order Entered in Hawaii State Court Against Bristol-Myers Squibb and Sanofi For Failing to Investigate and Disclose Ineffectiveness of Plavix

Subjects
United States. Food and Drug Administration -- Investigations, Bristol-Myers Squibb Co. -- Investigations, Sanofi S.A. -- Investigations, Drugs -- Prescribing, Pharmaceutical industry -- Investigations, Company legal issue, Business, international, Plavix (Medication)
Abstract

Hawaii Attorney General Clare E. Connors announced the entry of an $834 million state court order against Bristol-Myers Squibb Company and three U.S.-based subsidiaries of French pharmaceutical company Sanofi for [...]

Published
2021

27. Baron & Budd Obtains $834 Million Judgment Against Global Drug Manufacturers on Behalf of State of Hawai'i

Subjects
Bristol-Myers Squibb Co., Sanofi Synthelabo Inc., Pharmaceutical industry, General interest, News, opinion and commentary, Plavix (Medication)
Abstract

LOS ANGELES: Baron & Budd, P.C. has issued the following news release: Today, the nationally recognized attorneys from Baron & Budd obtained an $834,012,000 judgment against global pharmaceutical companies, Bristol-Myers [...]

Published
2021

29. New Indication for Plavix (Clopidogrel) Now Approved in the European Union

Subjects
Aspirin, Stroke (Disease), Drug approval, Clopidogrel, Business, international, Law, Plavix (Medication)
Abstract

The European Commission has approved an additional indication for Plavix (clopidogrel) to include its use in combination with aspirin in adult patients with moderate to high-risk Transient Ischemic Attack (TIA) [...]

Published
2021

30. Sanofi - New indication for Plavix now approved in the European Union

Subjects
Sanofi S.A., Pharmaceutical industry, European Union, Plavix (Medication)
Abstract

ENPNewswire-February 10, 2021--Sanofi - New indication for Plavix now approved in the European Union (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 09022021 - The European Commission has approved an additional indication [...]

Published
2021

31. France : New indication for Plavix (clopidogrel) now approved in the European Union

Subjects
Aspirin, Stroke (Disease), Drug approval, Clopidogrel, Business, international, Plavix (Medication)
Abstract

The European Commission has approved an additional indication for Plavix (clopidogrel) to include its use in combination with aspirin in adult patients with moderate to high-risk Transient Ischemic Attack (TIA) [...]

Published
2021

32. Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

Subjects
United States. Food and Drug Administration, Influenza vaccines, Company growth, Company earnings/profit, Business, international, Cablivi (Medication), Aubagio (Medication), Dupixent (Medication), Eloctate (Medication), Alprolix (Medication), Praluent (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Q4 2020 sales growth(2) of 4.2% and business EPS growth of 9.8% at CER - Specialty Care sales grew 18.3%, driven by strong Dupixent(R) performance [...]

Published
2021

33. T4 2020: Croissance du BNPA des activites(1) de pres de 10% a TCC

Subjects
United States. Food and Drug Administration, Influenza, Clopidogrel, Business, international, Cablivi (Medication), Aubagio (Medication), Dupixent (Medication), Eloctate (Medication), Alprolix (Medication), Praluent (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Croissance des ventes(2) de 4,2% et croissance du BNPA des activites de 9,8% a TCC au T4 2020 - Les ventes de la Medecine de [...]

Published
2021

34. Top 255 single-source brand name drugs, by prescriptions

Subjects
Drug wholesalers, Brand name products, Business, Pharmaceuticals and cosmetics industries, Retail industry, Cymbalta (Medication), Nexium (Medication), Nasonex (Medication), Singulair (Medication), Lantus (Medication), Advair Diskus (Medication), Spiriva (Medication), Plavix (Medication), Crestor (Medication)
Abstract

TOP 255 SINGLE-SOURCE BRAND NAME DRUGS, BY PRESCRIPTIONS RANK DRUG SUPPLIER NDC11 NO. 1 Nexium AstraZeneca 00186504031 2 Singulair Merck 00006011731 3 Plavix Bristol-Myers Squibb 63653117101 4 Cymbalta Lilly 00002327030 [...]

Published
2012

35. Top 450 single-source brand name drugs, by dollar sales

Subjects
Brand name products, Business, Pharmaceuticals and cosmetics industries, Retail industry, Lipitor (Medication), Cymbalta (Medication), Nexium (Medication), Singulair (Medication), Lantus (Medication), Advair Diskus (Medication), Celebrex (Medication), Spiriva (Medication), Plavix (Medication), Crestor (Medication)
Abstract

TOP 450 SINGLE-SOURCE BRAND NAME DRUGS, BY DOLLAR SALES RANK DRUG SUPPLIER NDC11 NO. 1 Nexium AstraZeneca 00186504031 2 Plavix BMS PrimaryCare 63653117101 3 Advair Diskus GlaxoSmithKline 00173069600 4 Singulair [...]

Published
2012

36. Top 20 pharma companies

Subjects
Merck & Company Inc. -- Rankings, Amgen Inc. -- Rankings, Pfizer Inc. -- Rankings, Boehringer Ingelheim GmbH -- Rankings, AstraZeneca PLC -- Rankings, Schering-Plough Corp. -- Rankings, Eli Lilly and Co. -- Rankings, Abbott Laboratories (Abbott Park, Illinois) -- Rankings, Takeda Pharma GmbH -- Rankings, Johnson & Johnson -- Rankings, Teva Pharmaceuticals USA Inc. -- Rankings, Novartis AG -- Rankings, GlaxoSmithKline PLC -- Rankings, Bristol-Myers Co. -- Rankings, Roche Holding AG -- Rankings, Biological products industry -- Rankings, Generic drugs -- Rankings, Alzheimer's disease -- Drug therapy, Pharmaceutical industry -- Rankings, Business, Health care industry, Seroquel (Medication), OxyContin (Medication), Nexium (Medication), Abilify (Medication), Remicade (Medication), Neulasta (Medication), Plavix (Medication), Lipitor (Medication), Enbrel (Medication), Singulair (Medication), Epogen (Medication), Actos (Medication), Advair Diskus (Medication), Crestor (Medication), Avastin (Medication)
Abstract

* Denotes IMS Health data ** Denotes SDI Promotional Audits & Kantar Media data Note: 2008 promotional totals for Pfizer, Merck and Roche include spending for Wyeth, Schering-Plough and Genentech [...]

Published
2010

37. In splintered drug market, industry seeks solutions

Author

Frederick, Jim

Subjects
Merck & Company Inc., Amgen Inc., Pfizer Inc., Apotex Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Eli Lilly and Co., Watson Pharmaceuticals Inc., Mylan Laboratories Inc., Johnson & Johnson, Mallinckrodt Inc., Novartis AG, GlaxoSmithKline PLC, Roche Holding AG, Drugs -- Economic aspects -- Market share -- Market research, United States economic conditions, Pharmaceutical industry -- Market share -- Industry forecasts -- Economic aspects -- Industry sales and revenue, Marketing research, Company market share, Business, Pharmaceuticals and cosmetics industries, Retail industry, Seroquel (Medication), Lipitor (Medication), Nexium (Medication), Abilify (Medication), Enbrel (Medication), Remicade (Medication), Singulair (Medication), Actos (Medication), Advair Diskus (Medication), Plavix (Medication)
Abstract

If you're a pharmaceutical manufacturer, wholesaler or retailer, that distinct chill you've been feeling at your place of business over the past couple of years isn't just some abstract news [...]

Published
2010

38. The pharma top 50: our sister title, Pharmaceutical Executive, brings you the definitive guide to the world's top pharma companies

Subjects
Merck & Company Inc., Merck KGAA, Amgen Inc., Bristol-Myers Squibb Co., Pfizer Inc., Boehringer Ingelheim GmbH, AstraZeneca PLC, Eli Lilly and Co., Schering-Plough Corp., Novo Nordisk A/S, Abbott Laboratories (Abbott Park, Illinois), Servier Laboratories Ltd., Sanofi-Aventis S.A., Wyeth, Bayer AG, Johnson & Johnson, Novartis AG, GlaxoSmithKline PLC, Roche Holding AG, Seroquel (Medication), Lipitor (Medication), Nexium (Medication), Enbrel (Medication), Remicade (Medication), Singulair (Medication), Zyprexa (Medication), Advair Diskus (Medication), Lovenox (Medication), Plavix (Medication), Drugs -- Market size, Pharmaceutical industry -- Market size -- Rankings -- Growth, Business, Pharmaceuticals and cosmetics industries, Company growth, Market size, Rankings, Growth
Abstract

THE PHARMA TOP 50 1. Pfizer 2. GlaxoSmithKline 3. Sanofi-Aventis 4. Novartis 5. AstraZeneca 6. Johnson & Johnson 7. Merck 8. Roche 9. Eli Lilly 10. Wyeth 11. Bristol-Myers Squibb [...]

Published
2009

40. Le CHMP recommande l'approbation de Plavix(R) (clopidogrel) en association avec de l'aspirine apres certaines formes d'accident vasculaire cerebral de l'adulte

Subjects
Sanofi S.A. -- Accidents, Clopidogrel, Pharmaceutical industry -- Accidents, Business, international, Plavix (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Le CHMP recommande l'approbation de Plavix(R) (clopidogrel) en association avec de l'aspirine apres certaines formes d'accident vasculaire cerebral de l'adulte - Le CHMP rend un [...]

Published
2020

42. Croissance du BNPA(1) des activites de 8,8% a TCC au troisieme trimestre 2020

Subjects
United States. Food and Drug Administration, Palbociclib, Carfilzomib, Influenza, Franchises, Business, international, Dupixent (Medication), Eloctate (Medication), Praluent (Medication), Libtayo (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- La croissance(2) des ventes au T3 2020 a ete soutenue par la forte demande de Dupixent(R) et de vaccins grippe. - Le chiffre d'affaires a [...]

Published
2020

43. Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER

Subjects
United States. Food and Drug Administration, Influenza vaccines, Evidence-based medicine, Franchises, COVID-19, Company growth, Company earnings/profit, Business, international, European Union. European Commission -- Growth, Dupixent (Medication), Menactra (Vaccine), Eloctate (Medication), Praluent (Medication), Libtayo (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Q3 2020 sales growth(2) driven by strong Dupixent(R) and flu vaccines demand. - Net sales were EUR9,479 million, up 5.7%(2) at CER and down 0.2% [...]

Published
2020

44. This Biden Superfan Can't Stop Tweeting Fake Garbage

Subjects
COVID-19, General interest, News, opinion and commentary, Twitter (Online social network), Plavix (Medication)
Abstract

Minutes before Donald Trump announced via tweet that he had COVID-19, Joe Biden superfan Jon Cooper tried to break some news of his own about the president's health. Trump, Cooper [...]

Published
2020

45. Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation

Subjects
United States. Food and Drug Administration, Carfilzomib, Influenza vaccines, Pomalidomide, Company growth, Business, international, Dupixent (Medication), Eloctate (Medication), Lantus (Medication), Praluent (Medication), Libtayo (Medication), Plavix (Medication), Amaryl (Medication), Toujeo (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation Q2 2020 sales results reflect the strong performance of Dupixent(R) more than offset by [...]

Published
2020

46. Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

Subjects
United States. Food and Drug Administration, Sanofi S.A., Pharmaceutical industry, Dupixent (Medication), Lantus (Medication), Praluent (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

ENPNewswire-February 7, 2020--Sanofi delivers strong 2019 business EPS growth of 6.8% at CER (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 06022020 - Sanofi Chief Executive Officer, Paul Hudson, commented: 'I am [...]

Published
2020

47. Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

Subjects
United States. Food and Drug Administration, Financial statements -- Forecasts and trends, Economic forecasting -- Forecasts and trends, Finance, Market trend/market analysis, Business, international, Dupixent (Medication), Eloctate (Medication), Lantus (Medication), Praluent (Medication), Lemtrada (Medication), Plavix (Medication), Toujeo (Medication)
Abstract

(GLOBE NEWSWIRE via COMTEX) -- Sanofi delivers strong 2019 business EPS growth of 6.8% at CER Q4 2019 Change Change 2019 Change Change at CER at CER IFRS net sales [...]

Published
2020

49. Boom and bust for blockbuster drugs: as reliance on blockbuster drug revenue increases, weaker pipelines and generic competition create strategic challenges for pharmaceutical CEOs

Author

Van Arnum, Patricia

Subjects
Merck & Company Inc. -- Finance -- Company sales and earnings, Aventis Pharmaceuticals Inc. -- Company sales and earnings -- Finance, Pfizer Inc. -- Finance -- Company sales and earnings, GSK PLC -- Finance -- Company sales and earnings, Bristol-Myers Squibb Co. -- Finance -- Company sales and earnings, Forest Laboratories Inc. -- Finance -- Company sales and earnings, Sanofi Synthelabo, F. Hoffmann-La Roche Ltd. -- Company sales and earnings -- Finance, AstraZeneca PLC -- Company sales and earnings -- Finance, Eli Lilly and Co. -- Company sales and earnings -- Finance, Bayer Corp. -- Finance -- Company sales and earnings, Antidepressants, Antiasthmatic agents, Antimitotic agents, Bupropion, Infliximab, Thromboxanes, Quetiapine, Metformin, Hypoglycemic agents, Fentanyl, Fluoxetine, Nifedipine, Antihypertensive drugs, Chemical industry -- Industry forecasts -- Industry sales and revenue -- Company sales and earnings, Ceftriaxone sodium, Pesticides industry -- Industry forecasts -- Industry sales and revenue -- Company sales and earnings, Antineoplastic agents, Enalaprilat, Enalapril, Pharmaceutical industry -- Finance -- Industry sales and revenue -- Industry forecasts -- Company sales and earnings, Antiulcer drugs, Montelukast, Citalopram, Herbicides -- Industry forecasts -- Industry sales and revenue -- Company sales and earnings, Lisinopril, Drugs -- Finance, Ceftriaxone, Paclitaxel, Company financing, Company earnings/profit, Business, Chemicals, plastics and rubber industries, Seroquel (Medication), Taxol (Medication), Zestril (Medication), Ambien (Medication), Lovenox (Medication), Celexa (Medication), Prinzide (Medication), MabThera (Medication), Vasotec (Medication), Zyrtec (Medication), Rituxan (Medication), Actos (Medication), Seretide (Medication), Remicade (Medication), Duragesic (Transdermal patch), Adalat (Medication), Prinvil (Medication), Wellbutrin (Medication), Plavix (Medication), Avandia (Medication), Glucophage (Medication), Rocephin (Medication), Singulair (Medication), Nexium 24HR (Medication), Advair Diskus (Medication), Prozac (Medication) -- Finance
Abstract

Pharmaceutical chief executives heading into 2004 face a difficult task in meeting investor expectations. The market is changing. While blockbuster drugs--that is, drugs achieving sales of $1 billion of more--are [...]

Published
2003

50. High Court's jurisdictional ruling curtails mass tort options

Subjects
United States. Supreme Court, Bristol-Myers Squibb Co., Legal liability, Pharmaceutical industry, Business, general, Business, Law, Plavix (Medication)
Abstract

Bristol-Meyers Squibb Co. v. Superior Court of California, 137 S. Ct. 1773 (U.S. June 19, 2017). California courts lacked specific jurisdiction to entertain product liability claims against the manufacturer of [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results